source
- FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancerSummit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
- FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival dataThe FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…